Relationship between Human Telomerase Reverse Transcriptase Gene and Some microRNAs Expression Levels in Patients with Bladder Cancer

Sura Mouaid Abbas; Maysaa Abdul Razzaq Dhahi

doi:10.54133/ajms.v7i1.1229

Authors

Sura Mouaid Abbas Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0001-5132-0504
Maysaa Abdul Razzaq Dhahi Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq https://orcid.org/0000-0003-3436-8084

DOI:

https://doi.org/10.54133/ajms.v7i1.1229

Keywords:

Bladder cancer, Gene expression levels, hTERT, miRNAs

Abstract

Background: Bladder cancer (BC) is the fourth most prevalent cancer among the top ten malignancies, and human telomerase reverse transcriptase (hTERT) played a role in its pathogenesis. Objective: To investigate the link between hTERT expression levels and miRNA-29c, miRNA-125, miRNA-141, miRNA-145, and miRNA-205 expression levels in BC patients. Methods: A total of 149 tissue biopsies and/or urine samples were collected from patients with urinary tract complications, including BC patients, as well as patients who served as negative controls for BC (negative cystoscopy, prostate cancer patients), and healthy people. To measure the hTERT gene expression level, total RNA was extracted and reverse-transcribed to cDNA. Then, quantitative real-time PCR was performed using specific primer sets. Results: hTERT expression levels in BC patients were significantly higher; however, there was no statistically significant difference between the grade of non-muscle invasive BC or the stages of muscle invasion in urine or tissue biopsy samples. The expression of hTERT and miRNAs (miRNA-29c, miRNA-125, miRNA-141, miRNA-145, and miRNA-205) genes in urine and tissue biopsies was significantly correlated. BC patients had upregulated hTERT expression levels in tissue biopsies and urine samples but lower expression levels of miR-141 and miR-205 compared to negative cystoscopy patients. Conclusions: The combination of miRNA and hTERT expression levels may serve as a good prognostic marker for predicting BC in both urine and tissue.

Downloads

Download data is not yet available.

References

Kittler R, Shiang C, Hutchinson R, Kollipara RK, Kapur P, Franto F, et al. Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer. Oncotarget. 2018;9(10):9415-9424. doi: 10.18632/oncotarget.24072. DOI: https://doi.org/10.18632/oncotarget.24072

Yahyazadeh R, Bashash D, Ghaffari P, Kord S, Safaroghli-Azar A, Ghaffari SH. Evaluation of hTERT, KRT7, and survivin in urine for noninvasive detection of bladder cancer using real-time PCR. BMC Urol. 2021;21(1):64. doi: 10.1186/s12894-021-00838-z. DOI: https://doi.org/10.1186/s12894-021-00838-z

Alnafakh RAA, Adishesh M, Button L, Saretzki G, Hapangama DK. Telomerase and telomeres in endometrial cancer. Front Oncol. 2019;9:344. doi: 10.3389/fonc.2019.00344. DOI: https://doi.org/10.3389/fonc.2019.00344

Colebatch AJ, Dobrovic A, Cooper WA. TERT gene: its function and dysregulation in cancer. J Clin Pathol. 2019;72(4):281-284. doi:10.1136/jclinpath-2018-205653. DOI: https://doi.org/10.1136/jclinpath-2018-205653

Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K. TERT-regulation and roles in cancer formation. Front Immunol. 2020;11:589929. doi: 10.3389/fimmu.2020.589929. DOI: https://doi.org/10.3389/fimmu.2020.589929

Trybek T, Kowalik A, Góźdź S, Kowalska A. Telomeres and telomerase in oncogenesis. Oncol Lett. 2020;20(2):1015-1027. doi: 10.3892/ol.2020.11659. DOI: https://doi.org/10.3892/ol.2020.11659

Di Nunno V, Aprile M, Bartolini S, Gatto L, Tosoni A, Ranieri L, et al. The biological and clinical role of the telomerase reverse transcriptase gene in glioblastoma: A potential therapeutic target? Cells. 2023;13(1):44. doi: 10.3390/cells13010044. DOI: https://doi.org/10.3390/cells13010044

Wen W, Mai SJ, Lin HX, Zhang MY, Huang JL, Hua X, et al. Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma. J Transl Med. 2019;17(1):186. doi: 10.1186/s12967-019-1923-2. DOI: https://doi.org/10.1186/s12967-019-1923-2

Smolarz B, Durczyński A, Romanowicz H, Szyłło K, Hogendorf P. miRNAs in cancer (Review of literature). Int J Mol Sci. 2022;23(5):2805. doi:10.3390/ijms23052805. DOI: https://doi.org/10.3390/ijms23052805

Menon A, Abd-Aziz N, Khalid K, Poh CL, Naidu R. miRNA: A promising therapeutic target in cancer. Int J Mol Sci. 2022;23(19):11502. doi: 10.3390/ijms231911502. DOI: https://doi.org/10.3390/ijms231911502

Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. Grading of urothelial carcinoma and the new "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". Eur Urol Focus. 2019;5(3):457-466. doi: 10.1016/j.euf.2018.01.003. DOI: https://doi.org/10.1016/j.euf.2018.01.003

Chen SM, Tao ZZ, Hua QQ, Liu D, Chi HM, Cai Q. Inhibition of human telomerase reverse transcriptase in hep-2 cells using short hairpin RNA expression vectors. Arch Otolaryngol Head Neck Surg. 2006;132(2):200-205. doi: 10.1001/archotol.132.2.200. DOI: https://doi.org/10.1001/archotol.132.2.200

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-408. doi: 10.1006/meth.2001.1262 DOI: https://doi.org/10.1006/meth.2001.1262

Serrano D, Bleau AM, Fernandez-Garcia I, Fernandez-Marcelo T, Iniesta P, Ortiz-de-Solorzano C, et al. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Mol Cancer. 2011;10:96. doi: 10.1186/1476-4598-10-96. DOI: https://doi.org/10.1186/1476-4598-10-96

Abbas SM, Dhahi MA, Muhammad SH. Evaluation of gene expression level of miRNA-29c, miRNA-125, miRNA-141, miRNA-145 and miRNA-205 as predisposing factors for transitional cell carcinoma-bladder cancer in Iraqi patients. Iraqi J Sci. 2023;64(8):3799-3811. doi: 10.24996/ijs.2023.64.8.7. DOI: https://doi.org/10.24996/ijs.2023.64.8.7

Batista R, Vinagre N, Meireles S, Vinagre J, Prazeres H, Leão R, et al. Biomarkers for bladder cancer diagnosis and surveillance: A comprehensive review. Diagnostics (Basel). 2020;10(1):39. doi: 10.3390/diagnostics10010039. DOI: https://doi.org/10.3390/diagnostics10010039

Xie XY, Yang X, Zhang JH, Liu ZJ. Analysis of hTERT expression in exfoliated cells from patients with bladder transitional cell carcinomas using SYBR green real-time fluorescence quantitative PCR. Ann Clin Biochem. 2007;44(Pt 6):523-528. doi: 10.1258/000456307782268093. DOI: https://doi.org/10.1258/000456307782268093

Mezzasoma L, Antognelli C, Del Buono C, Stracci F, Cottini E, Cochetti G, et al. Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer. BMC Urol. 2010;10:17. doi: 10.1186/1471-2490-10-17. DOI: https://doi.org/10.1186/1471-2490-10-17

Eckburg A, Dein J, Berei J, Schrank Z, Puri N. Oligonucleotides and microRNAs targeting telomerase subunits in cancer therapy. Cancers (Basel). 2020;12(9):2337. doi: 10.3390/cancers12092337 DOI: https://doi.org/10.3390/cancers12092337

Borkowska EM, Konecki T, Pietrusiński M, Borowiec M, Jabłonowski Z. MicroRNAs which can prognosticate aggressiveness of bladder cancer. Cancers (Basel). 2019;11(10):1551. doi: 10.3390/cancers11101551. DOI: https://doi.org/10.3390/cancers11101551

Yik MY, Azlan A, Rajasegaran Y, Rosli A, Yusoff NM, Moses EJ. Mechanism of human telomerase reverse transcriptase (hTERT) regulation and clinical impacts in leukemia. Genes (Basel). 2021;12(8):1188. doi: 10.3390/genes12081188. DOI: https://doi.org/10.3390/genes12081188

Abdelgawad A, Mosbah A, Eissa L. Expression of microRNA-155 and human telomerase reverse transcriptase in patients with bladder cancer. Egypt J Bas Appl Sci. 2020;7(1):315-322. doi: 10.1080/2314808X.2020.1816337. DOI: https://doi.org/10.1080/2314808X.2020.1816337